Abstract
The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Infectious Disorders - Drug Targets
Title: Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Volume: 8 Issue: 3
Author(s): Yuping Lai and Richard L. Gallo
Affiliation:
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Abstract: The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Export Options
About this article
Cite this article as:
Lai Yuping and Gallo L. Richard, Toll-Like Receptors in Skin Infections and Inflammatory Diseases, Infectious Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/1871526510808030144
DOI https://dx.doi.org/10.2174/1871526510808030144 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Concurrent Methicillin-Resistant <i>Staphylococcus aureus Septicemia</i> and Thyroid Abscess in a Young Male with Dengue
Infectious Disorders - Drug Targets Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research Additive Effect of MCP in Combination with Cefotaxime Against Staphylococcus aureus
Medicinal Chemistry Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Emergence of Methicillin-Resistant Staphylococcus aureus (MRSA) as a Public-Health Threat and Future Directions of Antibiotic Therapy for MRSA Infections
Anti-Infective Agents Proteomic and Bioinformatics Tools to Understand Virulence Mechanisms in Staphylococcus aureus
Current Proteomics Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Antimicrobial and Antifungal Properties of Leaves to Root Extracts and Saponin Fractions of <i>Chlorophytum borivilianum</i>
Current Bioactive Compounds HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry